ZBIO Zenas Biopharma Inc.

$ZBIO - This stock is heading to $45 + . ZBIO has roughly a 65–75% chance of a positive SLE readout, based on encouraging prior clinical data and strong validation of obexelimab’s mechanism in other autoimmune diseases. A strong positive readout could be a major catalyst for ZBIO and will drive the stock price north of $45

$ZBIO - Based on the previous data and selective population there is very high probability that SLE data is going to be great and take this stock to $45+ range

$ZBIO Data are due soon. Skeptics are here but judging from the low volume, they will be punished. The stock deserves to be in the $60-80’s for the potential and pipeline. JMO

$ZBIO plans to showcase seven MS posters and a BTK-inhibition symposium at MSToronto2026.

$ZBIO 12 mio shares short, we know who controls the price these days... no one buys anymore ahead of binary events, a perfect opportunity to hammer the price lower, needs very little volume, unfortunatly

$ZBIO previews new obexelimab data at Oct 8-10 IgG4ward! symposium and Nov ACR Convergence.